Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups